It’s checkmate for Opdivo small-cell lung cancer trial
Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
Browsing: Clinical trials
T-VEC: what’s next for oncolytic virotherapy and immuno-oncology?
Find out about T-VEC, which was the first oncolytic virotherapy that was approved by the FDA as well as the CheckMate 141 trial.
What are the top 5 breast cancer advancements of 2018?
In this opinion piece from our Editor, Jade Parker, you can discover the top 5 breast cancer advancements of 2018.
CTLA-4, PD-1 and the Nobel Prize: a patient’s reaction to immunotherapy recognition
This past week, the Nobel Prizes in Physiology or Medicine was awarded to research scientists…
2018 Nobel Prize in Medicine awarded to James P Allison and Tasuku Honjo
Tasuku Honjo and James P Allison have been awarded the 2018 Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation.
FDA approves first and only treatment for advanced cutaneous squamous cell carcinoma
The US FDA has approved Libtayo®, the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the USA.
IASLC 19th WCLC: highlights and the biggest headlines
In this round up we provide you with the biggest headlines and highlights from the IASLC World Conference on Lung Cancer (WCLC) the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
Could urine liquid biopsies help monitor bladder cancer treatment?
Researchers have demonstrated for the first time that immune cells in the urine of bladder cancer patients accurately reflect those in the tumor environment.
IMpower133: Atezolizumab extends overall survival for extensive-stage small-cell lung cancer
A Phase III trial involving the combination of immunotherapy and chemotherapy has seen significantly improved overall survival and progression-free survival in extensive-stage small-cell lung cancer patients.
New tool could predict how cancer will resist drugs before they are given to patients
Scientists have discovered a new computer software system that can be utilized in order to forecast how certain cancers may respond to a new drug even before it has been given to patients.
